Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Corbus Pharmaceuticals (CRBP)
NASDAQ:CRBP
RESEARCH TOOLSreports
Holding CRBP?
Track your performance easily
CRBP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.11 - $61.90
Previous CloseN/A
Volume39.58K
Average Volume (3M)263.80K
Market Cap
$128.13M
Enterprise Value$91.83M
Total Cash (Recent Filing)$14.99M
Total Debt (Recent Filing)$4.63K
Price to Earnings (P/E)―
Beta2.51
Next Earnings
Mar 18, 2025EPS Estimate
-1.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.70
Shares Outstanding12,179,482
10 Day Avg. Volume205,981
30 Day Avg. Volume263,796
Standard Deviation0.55
R-Squared0.06
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.19
Forecast
1Y Price Target
$58.33Price Target Upside506.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Corbus Pharmaceuticals News
PremiumCompany Announcements
Corbus Pharmaceuticals Advances with FDA Fast Track Designation
PremiumCompany Announcements
Corbus Pharmaceuticals Reports Q3 2024 Financials and Updates
Bulls Say, Bears Say
Bulls Say
Clinical DataThe release of disappointing clinical data from a key competitor is seen as a positive read-through for CRBP, potentially benefiting its stock performance.
Drug DevelopmentCRB-701's promising initial P1 data from its Chinese partner shows a better safety profile with no dose-limiting toxicities or cases of peripheral neuropathy or rash.
Regulatory ProgressCorbus Pharmaceuticals recently received Fast Track Designation from the FDA for the anti-nectin-4 antibody drug conjugate, CRB-701, for the treatment of relapsed or refractory metastatic cervical cancer.
Bears Say
Clinical DataBicycle Therapeutics' shares fell sharply following the release of their clinical data, indicating market disappointment.
Financial ManagementThe annualized cash burn is $40.0 million, which requires careful financial management to sustain operations over the long term.
Investor SentimentThe company has a high short interest percentage of 21.9%, which may indicate skepticism or concerns from investors.
---
Ownership Overview
31.09% Insiders
8.20% Mutual Funds
0.07% Other Institutional Investors
49.60% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRBP FAQ
What was Corbus Pharmaceuticals’s price range in the past 12 months?
Corbus Pharmaceuticals lowest stock price was $10.11 and its highest was $61.90 in the past 12 months.
What is Corbus Pharmaceuticals’s market cap?
Corbus Pharmaceuticals’s market cap is $128.13M.
When is Corbus Pharmaceuticals’s upcoming earnings report date?
Corbus Pharmaceuticals’s upcoming earnings report date is Mar 18, 2025 which is in 46 days.
How were Corbus Pharmaceuticals’s earnings last quarter?
Corbus Pharmaceuticals released its earnings results on Nov 07, 2024. The company reported -$1.15 earnings per share for the quarter, missing the consensus estimate of -$0.952 by -$0.198.
Is Corbus Pharmaceuticals overvalued?
According to Wall Street analysts Corbus Pharmaceuticals’s price is currently Undervalued.
Does Corbus Pharmaceuticals pay dividends?
Corbus Pharmaceuticals does not currently pay dividends.
What is Corbus Pharmaceuticals’s EPS estimate?
Corbus Pharmaceuticals’s EPS estimate is -1.24.
How many shares outstanding does Corbus Pharmaceuticals have?
Corbus Pharmaceuticals has 12,179,482 shares outstanding.
What happened to Corbus Pharmaceuticals’s price movement after its last earnings report?
Corbus Pharmaceuticals reported an EPS of -$1.15 in its last earnings report, missing expectations of -$0.952. Following the earnings report the stock price went down -2.062%.
Which hedge fund is a major shareholder of Corbus Pharmaceuticals?
Among the largest hedge funds holding Corbus Pharmaceuticals’s share is Driehaus Capital Management LLC. It holds Corbus Pharmaceuticals’s shares valued at 3M.
---
Corbus Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$58.33 (506.34% Upside)
$58.33 (506.34% Upside)
Blogger Sentiment
Bullish
CRBP Sentiment 75%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 171.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
39.70%
12-Months-Change
Fundamentals
Return on Equity
-25.71%
Trailing 12-Months
Asset Growth
352.47%
Trailing 12-Months
Company Description
Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.
---
CRBP Stock 12 Month Forecast
Average Price Target
$58.33
▲(506.34% Upside)
Technical Analysis
Best Analysts Covering CRBP
1 Year
1 Year Success Rate
1/10 ratings generated profit
1 Year Average Return
-22.29%
reiterated a buy rating 3 months ago
Copying Jeff Jones's trades and holding each position for 1 Year would result in 10.00% of your transactions generating a profit, with an average return of -22.29% per trade.
---